CD44v6: a target for antibody-based cancer therapy

被引:133
作者
Heider, KH
Kuthan, H
Stehle, G
Munzert, G
机构
[1] Boehringer Ingelheim Austria, A-1121 Vienna, Austria
[2] Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach, Germany
关键词
bivatuzumab; CD44v6; immunohistochemistry; monoclonal antibody; tumour therapy;
D O I
10.1007/s00262-003-0494-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The human CD44 gene encodes type 1 transmembrane glycoproteins involved in cell-cell and cell-matrix interactions. The structural heterogeneity of the gene products is caused primarily by alternative splicing of at least 10 out of 20 exons. Certain CD44 variant isoforms, in particular those containing CD44 variant domain 6 (CD44v6), have been implicated in tumourigenesis, tumour cell invasion and metastasis. Here we will give an overview of immunohistochemically determined CD44v6 expression in human malignancies (primary epithelial and nonepithelial tumours as well as metastases) and normal tissues, and review several examples of the clinical use of CD44v6-specific antibodies. In nonmalignant tissues, CD44v6 expression is essentially restricted to a subset of epithelia. Intense and homogeneous expression of CD44v6 was reported for the majority of squamous cell carcinomas and a proportion of adenocarcinomas of differing origin, but was rarely seen in nonepithelial tumours. This expression pattern has made CD44v6 an attractive target for antibody-guided therapy of various types of epithelium-derived cancers.
引用
收藏
页码:567 / 579
页数:13
相关论文
共 139 条
  • [1] CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE
    ARUFFO, A
    STAMENKOVIC, I
    MELNICK, M
    UNDERHILL, CB
    SEED, B
    [J]. CELL, 1990, 61 (07) : 1303 - 1313
  • [2] CD44: One ligand, two functions
    Aruffo, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (10) : 2191 - 2192
  • [3] Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma
    Ayhan, A
    Baykal, C
    Al, A
    Ayhan, A
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 83 (03) : 569 - 574
  • [4] Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance
    Ayhan, A
    Tok, EC
    Bildirici, I
    Ayhan, A
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 80 (03) : 355 - 358
  • [5] Beham-Schmid C, 1998, J PATHOL, V186, P383
  • [6] Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells
    Bendall, LJ
    Bradstock, KF
    Gottlieb, DJ
    [J]. LEUKEMIA, 2000, 14 (07) : 1239 - 1246
  • [7] CD44 ISOFORMS CONTAINING EXON V3 ARE RESPONSIBLE FOR THE PRESENTATION OF HEPARIN-BINDING GROWTH-FACTOR
    BENNETT, KL
    JACKSON, DG
    SIMON, JC
    TANCZOS, E
    PEACH, R
    MODRELL, B
    STAMENKOVIC, I
    PLOWMAN, G
    ARUFFO, A
    [J]. JOURNAL OF CELL BIOLOGY, 1995, 128 (04) : 687 - 698
  • [8] Boettger Thomas C., 1998, Cancer, V83, P1074
  • [9] Börjesson PKE, 2003, CLIN CANCER RES, V9, p3961S
  • [10] Borland G, 1998, IMMUNOLOGY, V93, P139